Market Research Life Sciences Market Research Diagnostics Market Research Medical Imaging Market Research Nuclear Medicine Market Research

Nuclear Medicine Market (Type: Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine; Application: Cardiology, Neurology, Oncology, Pulmonology, Gastroenterology and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 202

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 187 Pages Transparency Market Research Pvt. Ltd. June, 2023 TNPR18094202
Best Price Guarantee
Price from $5,795
Length 187 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date June, 2023
SKU TNPR18094202

Nuclear Medicine Market (Type: Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine; Application: Cardiology, Neurology, Oncology, Pulmonology, Gastroenterology and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Nuclear Medicine Market – Scope of Report


TMR’s report on the global Nuclear Medicine Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Nuclear Medicine Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Nuclear Medicine Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Nuclear Medicine Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Nuclear Medicine Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Nuclear Medicine Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Nuclear Medicine Market.

The report delves into the competitive landscape of the global Nuclear Medicine Market. Key players operating in the global Nuclear Medicine Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Nuclear Medicine Market profiled in this report.

Key Questions Answered in Global Nuclear Medicine Market Report
  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Nuclear Medicine Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Nuclear Medicine Market – Research Objectives and Research Approach

The comprehensive report on the global Nuclear Medicine Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Nuclear Medicine Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Nuclear Medicine.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nuclear Medicine Market
4. Market Overview
  4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
  4.2. Overview
  4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
  4.4. Global Nuclear Medicine Market Analysis and Forecast, 2017-2031
5. Key Insights
  5.1. Technological Advancements
  5.2. List of FDA Approved Radioisotopes
  5.3. No. of Nuclear Medicine Centers in Major Countries
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Nuclear Medicine Market Analysis and Forecast, by Type
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Diagnostic Nuclear Medicine
6.3.1.1. PECT Radiopharmaceuticals
6.3.1.2. PET Radiopharmaceuticals
6.3.2. Therapeutic Nuclear Medicine
6.3.2.1. Alpha Emitters
6.3.2.2. Beta Emitters
6.3.2.3. Brachytherapy Isotopes
  6.4. Market Attractiveness Analysis, by Type
7. Global Nuclear Medicine Market Analysis and Forecast, by Application
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Cardiology
7.3.2. Neurology
7.3.3. Oncology
7.3.4. Pulmonology
7.3.5. Gastroenterology
7.3.6. Others
  7.4. Market Attractiveness Analysis, by Application
8. Global Nuclear Medicine Market Analysis and Forecast, by End-user
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.2.1. Individual Practice
8.3.2.2. Group Practice
8.3.3. Research Institutes
  8.4. Market Attractiveness Analysis, by End-user
9. Global Nuclear Medicine Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
  9.3. Market Attractiveness Analysis, by Region
10. North America Nuclear Medicine Market Analysis and Forecast
  10.1. Introduction
10.1.1. Key Findings
  10.2. Market Value Forecast, by Type, 2017-2031
10.2.1. Diagnostic Nuclear Medicine
10.2.1.1. PECT Radiopharmaceuticals
10.2.1.2. PET Radiopharmaceuticals
10.2.2. Therapeutic Nuclear Medicine
10.2.2.1. Alpha Emitters
10.2.2.2. Beta Emitters
10.2.2.3. Brachytherapy Isotopes
  10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Cardiology
10.3.2. Neurology
10.3.3. Oncology
10.3.4. Pulmonology
10.3.5. Gastroenterology
10.3.6. Others
  10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.2.1. Individual Practice
10.4.2.2. Group Practice
10.4.3. Research Institutes
  10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
  10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Nuclear Medicine Market Analysis and Forecast
  11.1. Introduction
11.1.1. Key Findings
  11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Diagnostic Nuclear Medicine
11.2.1.1. PECT Radiopharmaceuticals
11.2.1.2. PET Radiopharmaceuticals
11.2.2. Therapeutic Nuclear Medicine
11.2.2.1. Alpha Emitters
11.2.2.2. Beta Emitters
11.2.2.3. Brachytherapy Isotopes
  11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Cardiology
11.3.2. Neurology
11.3.3. Oncology
11.3.4. Pulmonology
11.3.5. Gastroenterology
11.3.6. Others
  11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.2.1. Individual Practice
11.4.2.2. Group Practice
11.4.3. Research Institutes
  11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
  11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Nuclear Medicine Market Analysis and Forecast
  12.1. Introduction
12.1.1. Key Findings
  12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Diagnostic Nuclear Medicine
12.2.1.1. PECT Radiopharmaceuticals
12.2.1.2. PET Radiopharmaceuticals
12.2.2. Therapeutic Nuclear Medicine
12.2.2.1. Alpha Emitters
12.2.2.2. Beta Emitters
12.2.2.3. Brachytherapy Isotopes
  12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Cardiology
12.3.2. Neurology
12.3.3. Oncology
12.3.4. Pulmonology
12.3.5. Gastroenterology
12.3.6. Others
  12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Diagnostic Centers
12.4.2.1. Individual Practice
12.4.2.2. Group Practice
12.4.3. Research Institutes
  12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
  12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Nuclear Medicine Market Analysis and Forecast
  13.1. Introduction
13.1.1. Key Findings
  13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Diagnostic Nuclear Medicine
13.2.1.1. PECT Radiopharmaceuticals
13.2.1.2. PET Radiopharmaceuticals
13.2.2. Therapeutic Nuclear Medicine
13.2.2.1. Alpha Emitters
13.2.2.2. Beta Emitters
13.2.2.3. Brachytherapy Isotopes
  13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Cardiology
13.3.2. Neurology
13.3.3. Oncology
13.3.4. Pulmonology
13.3.5. Gastroenterology
13.3.6. Others
  13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Diagnostic Centers
13.4.3. Research Institutes
  13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
  13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Nuclear Medicine Market Analysis and Forecast
  14.1. Introduction
14.1.1. Key Findings
  14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Diagnostic Nuclear Medicine
14.2.1.1. PECT Radiopharmaceuticals
14.2.1.2. PET Radiopharmaceuticals
14.2.2. Therapeutic Nuclear Medicine
14.2.2.1. Alpha Emitters
14.2.2.2. Beta Emitters
14.2.2.3. Brachytherapy Isotopes
  14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Cardiology
14.3.2. Neurology
14.3.3. Oncology
14.3.4. Pulmonology
14.3.5. Gastroenterology
14.3.6. Others
  14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Diagnostic Centers
14.4.2.1. Individual Practice
14.4.2.2. Group Practice
14.4.3. Research Institutes
  14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
  14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competition Matrix (by tier and size of companies)
  15.2. Market Share Analysis, by Company, 2022
  15.3. Company Profiles
15.3.1. GE Healthcare
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Siemens Healthineers
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Philips Healthcare
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Cardinal Health
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Bracco Imaging S.p.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Curium Pharma
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Eckert & Ziegler
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Jubilant Radiopharma
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Lantheus Medical Imaging
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Nordion, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Advanced Accelerator Applications (AAA)
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. IBA Radiopharma Solutions
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. NorthStar Medical Radioisotopes
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Polatom
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Isotopia Molecular Imaging
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Type Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings